<DOC>
	<DOCNO>NCT01523314</DOCNO>
	<brief_summary>The research group develop new ocular drug delivery technology base cyclodextrin nanoparticles ( NP ) . The investigator plan develop test technology help treat diabetic macular edema ( DME ) . An important step research invention cyclodextrin nanoparticles , receive US patent . The investigator pre-clinical clinical work demonstrate investigator eye drop suspension cyclodextrin nano-particles superior conventional eye drop . They increase drug absorbance eye decrease systematic distribution drug , hence reduce side effect . Cyclodextrin nanoparticle eye drop deliver drug posterior part eye , thus solve one big obstacle ocular pharmacology .</brief_summary>
	<brief_title>Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Type 2 diabetes mellitus Pseudophakic study eye , i.e . IOL ( intra ocular lens ) cataract surgery Diabetic macular edema central macular thickness 300 Âµm OCT study eye . If eye DME , treatment apply eye thicker central macula OCT. Age 18 year old Glaucoma use glaucoma medication Known steroid IOP response Any infectious eye disease Treatment DME within 6 month , laser treatment , intravitreal subtenon injection steroid , intravitreal injection anti vascular endothelelial growth factor medication . Any eye surgery within 3 month eye condition e.g . corneal disorder , ocular hypotony retinal detachment . Crystalline lens present study eye Known allergy cyclodextrins , dexamethasone , ranibizumab component study medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>Cyclodextrin</keyword>
	<keyword>eye drop</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>macular laser</keyword>
</DOC>